Posted Nov. 8, 2013 at 10:43 a.m.

Premium Lock Hypertension drug drives Cornerstone to record 3Q revenue

Published: 2013-11-08 10:43:53
Updated: 2013-11-08 10:43:53

Cornerstone Therapeutics

Cardene I.V., an intravenous hypertension treatment that joined Cornerstone's portfolio with last year's acquisition of EKR Therapeutics, produced $20.7 million in third quarter sales - up 62 percent year over year - as that drug established itself the company's top seller....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2015 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders